World Library  
Flag as Inappropriate
Email this Article

Autoimmune hepatitis

Article Id: WHEBN0000660869
Reproduction Date:

Title: Autoimmune hepatitis  
Author: World Heritage Encyclopedia
Language: English
Subject: Hepatitis, Anti-nuclear antibody, Autoimmune polyendocrine syndrome type 1, Acute fatty liver of pregnancy, ICD-10 Chapter XI: Diseases of the digestive system
Collection: Hepatitis
Publisher: World Heritage Encyclopedia

Autoimmune hepatitis

Autoimmune hepatitis
Micrograph showing a lymphoplasmacytic interface hepatitis -- the characteristic histomorphologic finding of autoimmune hepatitis. Liver biopsy. H&E stain.
Classification and external resources
ICD-10 K75.4
ICD-9-CM 571.42
DiseasesDB 1150
MedlinePlus 000245
eMedicine med/366
MeSH D019693

Autoimmune hepatitis, formerly called lupoid hepatitis, is a chronic, autoimmune disease of the liver that occurs when the body's immune system attacks liver cells causing the liver to be inflamed. Common initial symptoms include fatigue or muscle aches or signs of acute liver inflammation including fever, jaundice, and right upper quadrant abdominal pain. Individuals with autoimmune hepatitis often have no initial symptoms and the disease is detected by abnormal liver function tests.[1]

Anomalous presentation of human leukocyte antigen (HLA) class II on the surface of liver cells, possibly due to genetic predisposition or acute liver infection, causes a cell-mediated immune response against the body's own liver, resulting in autoimmune hepatitis. This abnormal immune response results in inflammation of the liver, which can lead to further symptoms and complications such as fatigue and cirrhosis.[2] The disease may occur in any ethnic group and at any age, but is most often diagnosed in patients between age 40 and 50.[3]


  • Classification 1
  • Signs and symptoms 2
  • Cause 3
  • Diagnosis 4
  • Treatment 5
  • Prognosis 6
  • Epidemiology 7
  • History 8
  • References 9


Four subtypes are recognised, but the clinical utility of distinguishing subtypes is limited.

  1. positive ANA and SMA,[4] elevated immunoglobulin G (classic form, responds well to low dose steroids);
  2. positive LKM-1 (typically female children and teenagers; disease can be severe), LKM-2 or LKM-3;
  3. positive antibodies against soluble liver antigen[5] (this group behaves like group 1)[6] (anti-SLA, anti-LP)
  4. no autoantibodies detected (~20%) (of debatable validity/importance)

Signs and symptoms

Though there is a strong female predominance, men are also at risk for the disease. Patients may present with signs of chronic liver disease (abnormal liver function tests, fatigue, aches) or acute hepatitis (fever, jaundice, right upper quadrant abdominal pain).

"Autoimmune hepatitis usually occurs in women (70 %) between the ages of 15 and 40. Although the term "lupoid" hepatitis was originally used to describe this disease, patients with systemic lupus erythematosus do not have an increased incidence of autoimmune hepatitis and the two diseases are distinct entities. Patients usually present with evidence of moderate to severe hepatitis with elevated serum ALT and AST activities in the setting of normal to marginally elevated alkaline phosphatase and gamma-glutamyltranspeptidase activities. The patient will sometimes present with jaundice, fever and right upper quadrant pain and occasionally systemic symptoms such as arthralgias, myalgias, polyserositis and thrombocytopenia. Some patients will present with mild liver dysfunction and have only laboratory abnormalities as their initial presentation. Others will present with severe hepatic dysfunction."[7]


60% of patients have chronic hepatitis that may mimic viral hepatitis, but without serologic evidence of a viral infection. The disease usually affects women and is strongly associated with anti-smooth muscle autoantibodies.


The diagnosis of autoimmune hepatitis is best achieved with a combination of clinical, laboratory and histological findings after excluding other etiological factors (e.g. viral, hereditary, metabolic, cholestatic, and drug-induced diseases).

A number of specific antibodies found in the blood (antinuclear antibody (ANA), anti-smooth muscle antibody (SMA), liver/kidney microsomal antibody (LKM-1, LKM-2, LKM-3), anti soluble liver antigen and liver–pancreas antigen (SLA/LP) and anti-mitochondrial antibody (AMA)) are of use, as is finding an increased Immunoglobulin G level. However, the diagnosis of autoimmune hepatitis always requires a liver biopsy.

Expert opinion has been summarized by the International Autoimmune Hepatitis Group, which has published criteria which utilize clinical and laboratory data that can be used to help determine if a patient has autoimmune hepatitis.[8] A calculator based on those criteria is available online.[9]

Overlapping presentation with primary biliary cirrhosis and primary sclerosing cholangitis has been observed.[10]


Treatment may involve the prescription of immunosuppressive glucocorticoids, with or without azathioprine, and remission can be achieved in up to 60–80% of cases, although many will eventually experience a relapse.[11] Budesonide has been shown to be more effective in inducing remission than prednisone, and result in fewer adverse effects.[12] Those with autoimmune hepatitis who do not respond to glucocorticoids and azathioprine may be given other immunosuppressives like mycophenolate, cyclosporin, tacrolimus, methotrexate, etc. Liver transplantation may be required if patients do not respond to drug therapy or when patients present with fulminant liver failure.[13]


Autoimmune hepatitis is not a benign disease. Despite a good initial response to immunosuppression, recent studies suggest that the life expectancy of patients with autoimmune hepatitis is lower than that of the general population.[14][15][16] Additionally, presentation and response to therapy appears to differ according to race. For instance, African Americans appear to present with a more aggressive disease that is associated with worse outcomes.[17][18]


Autoimmune hepatitis has an incidence of 1-2 per 100,000 per year, and a prevalence of 10-20/100,000. As with most other autoimmune diseases, it affects women much more often than men (70%).[19] Liver enzymes are elevated, as may be bilirubin.


Autoimmune hepatitis was previously called "lupoid" hepatitis. It was originally described in the early 1950s.

Most patients do have an associated autoimmune disorder such as systemic lupus erythematosus. Thus, its name was previously lupoid hepatitis.

Because the disease has multiple different forms, and is not always associated with systemic lupus erythematosus, lupoid hepatitis is no longer used. The current name at present is autoimmune hepatitis (AIH).


  1. ^ Czaja, AJ (May 2004). "Autoimmune liver disease.". Current opinion in gastroenterology 20 (3): 231–40.  
  2. ^ National Digestive Diseases Information Clearinghouse. "Digestive Disease: Autoimmune Hepatitis". Archived from the original on 15 September 2010. Retrieved October 9, 2010. ,
  3. ^ Manns, MP; Czaja, AJ; Gorham, JD; Krawitt, EL; Mieli-Vergani, G; Vergani, D; Vierling, JM; American Association for the Study of Liver, Diseases (June 2010). "Diagnosis and management of autoimmune hepatitis.". Hepatology (Baltimore, Md.) 51 (6): 2193–213.  
  4. ^ Bogdanos DP, Invernizzi P, Mackay IR, Vergani D (June 2008). "Autoimmune liver serology: Current diagnostic and clinical challenges". World J. Gastroenterol. 14 (21): 3374–3387.  
  5. ^ "autoimmune hepatitis". 
  6. ^ "Medscape & eMedicine Log In". 
  7. ^ Krawitt, E. L. (1996). "Autoimmune hepatitis". New England Journal of Medicine 334 (14): 897–903.  
  8. ^ Alvarez F, Berg PA, Bianchi FB; et al. (November 1999). "International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis".  
  9. ^ "Autoimmune Hepatitis Calculator". Retrieved 2008-05-09. 
  10. ^ Washington MK (February 2007). "Autoimmune liver disease: overlap and outliers".  
  11. ^ Krawitt EL (January 1994). "Autoimmune hepatitis: classification, heterogeneity, and treatment". Am. J. Med. 96 (1A): 23S–26S.  
  12. ^ Manns, MP; Strassburg, CP (2011). "Therapeutic strategies for autoimmune hepatitis.". Digestive diseases (Basel, Switzerland) 29 (4): 411–5.  
  13. ^ Stephen J Mcphee, Maxine A Papadakis. Current medical diagnosis and treatment 2009 page.596
  14. ^ Hoeroldt, Barbara; McFarlane, Elaine; Dube, Asha; Basumani, Pandurangan; Karajeh, Mohammed; Campbell, Michael J.; Gleeson, Dermot (2011). "Long-term Outcomes of Patients With Autoimmune Hepatitis Managed at a Nontransplant Center". Gastroenterology 140 (7): 1980–1989.  
  15. ^ Ngu, Jing Hieng; Gearry, Richard Blair; Frampton, Chris Miles; Stedman, Catherine A.M. (2013). "Predictors of poor outcome in patients with autoimmune hepatitis: A population-based study". Hepatology 57 (6): 2399–2406.  
  16. ^ Ngu, Jing Hieng; Gearry, Richard Blair; Frampton, Chris Miles; Malcolm Stedman, Catherine Ann (2012). "Mortality and the risk of malignancy in autoimmune liver diseases: A population-based study in Canterbury, New Zealand". Hepatology 55 (2): 522–529.  
  17. ^ Lim, Kie N.; Casanova, Roberto L.; Boyer, Thomas D.; Bruno, Christine Janes (2001). "Autoimmune hepatitis in African Americans: presenting features and response to therapy". The American Journal of Gastroenterology 96 (12): 3390–3394.  
  18. ^ Verma, Sumita; Torbenson, Michael; Thuluvath, Paul J. (2007). "The impact of ethnicity on the natural history of autoimmune hepatitis". Hepatology 46 (6): 1828–1835.  
  19. ^ "Autoimmune Hepatitis". 
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.